Bringing the Oncology Community Together
Molecular Profiling Reveals Potential Targets in SCLC, Lung NETs
Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).
Read More >>
Financial Burden of Cancer Treatment Weighs Heavily on Patients
Fast Track Designation Granted to TAS-102 in mCRC
Few Agents Better Than Somatostatin Analogs for Symptom Control in Carcinoid Syndrome
Subcutaneous Octreotide May Offer Better Option for Managing NETS Symptoms
Axitinib Shows Promise in Carcinoid Tumors
Everolimus Improves Outcomes in Pancreatic Neuroendocrine Tumors
View More >>
- A Network of Your Peers
View more >>
Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETs
Dr. Reidy-Lagunes on Determining the Site of Unknown Primary in Metastatic NETs
Dr. Yao on Takeaways From the RADIANT-3 Trial
Most Popular Right Now
Tweets by @OncLive
New Metastatic Colorectal Cancer iPub
Insight from Fadi Braiteh, MD, and Robin Wachsman, RN, BS, OCN, CCRN, CBCN, on regorafenib in mCRC.
Treatment Considerations in Refractory CRC
Moderated by John L. Marshall, MD, this panel discussion includes expert perspectives from Johanna Bendell, MD, Marwan Fakih, MD, Heinz-Josef Lenz, MD, and Alan P. Venook, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.